Overview
Pharmaceutical

TOWA PHARMACEUTICAL CO.,LTD.

Towa Pharmaceutical is a leading Japanese generic drug (generic pharmaceuticals) manufacturer engaged in the research, development, and sales of generic medicines for the domestic and international markets. The company sells pharmaceutical products directly to medical institutions through its own sales network, as well as through agents, wholesalers, and other pharmaceutical manufacturers. In addition to its core generic drug business, Towa operates a health-related business encompassing a broad range of healthcare products and services, and has expanded internationally through its European subsidiary, Towa Pharma International Holdings, S.L., which conducts generic drug sales and contract R&D/manufacturing in Europe.

Market Cap
¥175B
US$1.12B
EV
¥362B
US$2.31B
Stock¥3,565▼-1.25%
US$1 = ¥157.05 (2026-10-22)
LTM EV/EBITDA
8.4
x
LTM EV/EBIT
14.8
x
LTM PER
21.2
x
LTM PBR
1.0
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▲+1.3%pt
100
Oct 23, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
175BUS$1.12BMarket Cap230BUS$1.46B+ Debt42.2BUS$269M− Cash1.04BUS$6.62M− Inv. Sec.362BUS$2.31BEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
166US$1.05B'22/3209US$1.33B'23/3228US$1.45B'24/3260US$1.65B'25/3274US$1.74B'26/3
EBITDA 5Y (¥B)
29.4US$187M'22/319.8US$126M'23/331.3US$199M'24/338.9US$248M'25/341.4US$264M'26/3
Net Income 5Y (¥B)
15.9US$101M'22/32.20US$14.0M'23/316.2US$103M'24/319.0US$121M'25/35.25US$33.4M'26/3
Capital Structure
44%
56%
EquityD/E 1.26xDebt
Liquidity vs Debt 5Y (¥B)▼ Net Debt
CashInv. Sec.Debt
33.3US$212M137US$869M'22/324.9US$159M162US$1.03B'23/330.3US$193M203US$1.29B'24/346.3US$295M231US$1.47B'25/346.3US$295M227US$1.44B'26/3
Shareholders
Top 10 hold 69.9%
1
Yoshida Office Co., Ltd.
40.83%
2
The Master Trust Bank of Japan, Ltd. (Trust Account)
7.77%
3
US BANK NATIONAL ASSOCIATION JP ACCTS TS (Standing Proxy: MUFG Bank, Ltd.)
3.98%
4
Custody Bank of Japan, Ltd. (Trust Account)
3.33%
5
Towa Pharmaceutical Kyoei-kai
3.13%
6
Custody Bank of Japan, Ltd. (Trust Account 4)
2.96%
7
Itsuro YOSHIDA
2.96%
8
TOWA PHARMACEUTICAL CO.,LTD. Employee Stock Ownership Association
2.03%
9
BNP PARIBAS LUXEMBOURG 2S JASDEC FIM LUXEMBOURG FUNDS UCITS ASSETS (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited)
1.63%
10
Yoshida Estate Co., Ltd.
1.32%
Management
11 officers
Itsuro YOSHIDA
Representative Director, President
May 1979 Joined the Company Oct 1983 General Manager, Accounting Department, the Company Dec 1983 Director, General Manager, Accounting Department, the Company Aug 1986 Director, General Manager, General Affairs Department, the Company Apr 1990 Director, Manager, President's Office, the Company Jun 1990 Senior Managing Director, Manager, President's Office, the Company Jun 1991 Senior Managing Director, Head of Production Division; concurrently Manager, President's Office, the Company Nov 1991 Senior Managing Director, Manager, President's Office, the Company Jun 1996 Representative Director, President, the Company (current) Oct 2003 Representative Director, Chairman, Jadolph Co., Ltd. (now Jadolph Pharmaceutical Co., Ltd.) Oct 2010 Representative Director, Chairman, Daichi Kasei Co., Ltd. Jun 2024 Director, Chairman, Jadolph Pharmaceutical Co., Ltd. (current)
1951-04-27
Osamu UCHIKAWA
Senior Managing Director
Aug 2017 Joined the Company; Advisor, Active Pharmaceutical Ingredients (API) Division Apr 2018 Executive Officer, Head of API Division, the Company Apr 2019 Senior Executive Officer, Head of API Division; concurrently in charge of Product Strategy Division and Fundamental Technology Division, the Company Apr 2021 Senior Executive Officer, Head of API Division; concurrently in charge of Product Planning, Fundamental Technology, Formulation Technology, Pharmaceutical Business and Pharmaceutical Development Divisions, the Company Jun 2021 Representative Director, Chairman, Daichi Kasei Co., Ltd. Apr 2022 Senior Executive Officer, Head of API Division; concurrently in charge of Quality Assurance, Product Planning, Fundamental Technology, Formulation Technology, Analytical Technology Center, Pharmaceutical Business and Pharmaceutical Development Divisions, the Company Apr 2023 Senior Executive Officer, in charge of R&D Division; concurrently in charge of Quality Assurance and Pharmaceutical Business Divisions, the Company Jun 2023 Director, the Company Jun 2025 Director, Chairman, Daichi Kasei Co., Ltd. (current); Managing Director, the Company Jun 2026 Senior Managing Director, the Company (current)
1958-12-25
Masaaki TAKEYASU
Managing Director
Apr 1988 Joined Shionogi & Co., Ltd. Apr 2006 General Manager, Corporate Planning Department, Shionogi & Co., Ltd. Apr 2008 General Manager, Marketing Department, Shionogi & Co., Ltd. Apr 2012 Executive Officer, Head of Overseas Business Division, Shionogi & Co., Ltd. Apr 2018 Executive Officer, General Manager, External Affairs Department, Shionogi & Co., Ltd. Apr 2019 Deputy Head, Corporate Management Division, H.U. Group Holdings, Inc. Jan 2021 Representative Director, President, Ishinban Co., Ltd. Jan 2023 Joined the Company; Deputy Head, Corporate Strategy Division Apr 2024 Attached to Corporate Strategy Division; in charge of Pharmaceutical Business Division, International Business Division, Business Promotion Division and Digital Health Planning and Promotion Office, the Company Representative Director, T-Square Solutions Co., Ltd. (current) Jun 2024 Director, the Company Jun 2026 Managing Director, the Company (current)
1964-11-03
Toshikazu KOKUBU
Director
Apr 2014 Joined the Company; Sales Division Apr 2020 General Manager, Regional Medical Strategy Department; concurrently General Manager, Next-Generation Business Promotion Department, Business Promotion Division, the Company Apr 2021 Executive Officer, Deputy Head, Business Promotion Division; concurrently General Manager, Regional Medical Strategy Department, the Company Apr 2022 Executive Officer, Head of Corporate Strategy Division; in charge of Human Resources Division, the Company Jun 2024 Executive Officer, Corporate Strategy Division; concurrently Human Resources, Administration, Accounting and Finance, Sales, Logistics and Production Divisions, the Company Jun 2024 Director, the Company (current)
1978-06-03
Tsuyoshi NAKAMURA
Director
Mar 2000 Joined the Company Apr 2012 Section Manager, Pharmaceutical Planning Department, Formulation Technology Center, the Company Apr 2017 Deputy General Manager, Pharmaceutical Planning Department, Formulation Technology Division, the Company Apr 2020 General Manager, Corporate Strategy Department, Corporate Strategy Division, the Company Apr 2021 General Manager, Corporate Strategy Department; concurrently General Manager, Corporate Planning Department, the Company Apr 2024 Head of Corporate Strategy Division, the Company Apr 2025 Executive Officer, Head of Corporate Strategy Division; concurrently Manager, President's Office, the Company Apr 2026 Executive Officer, Manager, President's Office; in charge of Corporate Strategy Division, the Company Jun 2026 Director, the Company (current)
1975-11-28
Masao TANAKA
Director (Audit and Supervisory Committee Member, Full-time)
Apr 2009 Joined the Company; Deputy General Manager, Internal Audit Department Apr 2011 General Manager, Internal Audit Department, the Company Oct 2016 General Manager, Public Relations and Investor Relations Office; concurrently General Manager, Human Resources Department, the Company Jun 2017 Apr 2019 Jun 2020 Apr 2021 Jul 2021 Jun 2024 Director, Head of Administration Division, the Company Director, in charge of Administration Division, the Company Director, Chairman, Protosera Co., Ltd. Representative Director, President, Protosera Co., Ltd. Director, the Company (Audit and Supervisory Committee Member) (current)
1954-07-04
Norikazu SAKAKI
Outside Director
Aug 1979 Joined Nihon Ciba-Geigy K.K. Jan 1994 Joined Bayer Yakuhin, Ltd. Mar 1997 Director, Shiga Plant Manager, Bayer Yakuhin, Ltd. Jul 2002 Representative Director, President, Bayer Yakuhin, Ltd. Jan 2007 Representative Director, Chairman, Bayer Yakuhin, Ltd. Apr 2010 Director, Chairman, Bayer Yakuhin, Ltd. May 2014 Outside Director, AnGes, Inc. (now AnGes, Inc.) Apr 2015 Outside Director, FunPep Co., Ltd. (current) Jun 2015 Outside Director, the Company Apr 2016 Outside Director, Solasia Pharma K.K. (current) Jun 2018 Outside Director, Gene Techno Science Co., Ltd. (now Kidswell Bio Co., Ltd.) (current) Jun 2019 Outside Director (Audit and Supervisory Committee Member), the Company Aug 2023 Outside Director, AwakApp Inc. (current) Jun 2024 Outside Director, the Company (current)
1948-04-17
Kaori OISHI
Outside Director (Audit and Supervisory Committee Member)
Oct 2001 Registered as Attorney-at-law Oct 2001 Joined Kitahama Partners (now Kitahama Partners, Gaikokuho Kyodo Jigyo) Jan 2013 Partner, Kitahama Partners (current) Jun 2017 Outside Director, PALTAC Corporation (current) Jun 2020 Outside Director (Audit and Supervisory Committee Member), the Company (current) Jun 2022 Outside Director, Fujitec Co., Ltd. Jun 2024 Outside Director, S-Read Co., Ltd. (current)
1977-04-21
Kenryo GOTO
Outside Director (Audit and Supervisory Committee Member)
Sep 1981 Joined Asahi Accounting Firm (now Ernst & Young ShinNihon LLC), Osaka Office Mar 1984 Registered as Certified Public Accountant May 2005 Member of the Firm (now Partner), Ernst & Young ShinNihon LLC Jul 2010 Executive Board Member; Head of Third Business Division, Osaka Office, Ernst & Young ShinNihon LLC Jul 2013 Managing Director, Ernst & Young ShinNihon LLC Jul 2015 Head of Osaka Office, Ernst & Young ShinNihon LLC Jul 2020 Opened Kenryo Goto Certified Public Accountant Office (current) Apr 2021 Auditor, Hyogo Medical University (current) Jun 2021 Outside Director (Audit and Supervisory Committee Member), the Company (current) Jun 2022 Outside Director, West Japan Railway Company (current) Jan 2024 Outside Audit & Supervisory Board Member, Hi-Lex Corporation (current)
1958-02-18
Nobuki ANDO
Outside Director (Audit and Supervisory Committee Member)
Apr 1978 Joined Nippon Express Co., Ltd. Jan 2002 General Manager, Seattle Branch, Nippon Express U.S.A., Inc. Feb 2004 General Manager, Los Angeles Air Cargo Branch, Nippon Express U.S.A., Inc. Oct 2008 General Manager, Sales Planning Department; concurrently General Manager, Customer Service Center, Nippon Express Co., Ltd. Jun 2011 Executive Officer, Sales Planning Department, Sales Division No. 3 and Customer Service Center, Nippon Express Co., Ltd. May 2013 Executive Officer, Sales Planning Department, Global Logistics Sales Department and Customer Service Center, Nippon Express Co., Ltd. May 2014 Managing Executive Officer, Nippon Express Co., Ltd. May 2015 Chairman, Nippon Express Health Insurance Union Apr 2017 Chairman, Alumni Association and Councilor, Ryutsu Keizai University Gakuen (now Ryutsu Keizai University) Oct 2017 Chairman, Japan Health Insurance Association Apr 2022 Director and Councilor, Ryutsu Keizai University Gakuen (current) Jun 2024 Outside Director (Audit and Supervisory Committee Member), the Company (current)
1954-04-30
Muneya TANIGUCHI
Outside Director (Audit and Supervisory Committee Member)
Apr 1985 Joined The Mitsubishi Bank, Ltd. (now MUFG Bank, Ltd.) Jun 2011 Executive Officer, General Manager, Third Sales Department, First Sales Division, MUFG Bank, Ltd. May 2015 Managing Executive Officer, Head of Third Sales Division; in charge of Financial Institutions and Public Corporations Department, MUFG Bank, Ltd. Apr 2019 Senior Managing Executive Officer, Western Japan Regional Head, MUFG Bank, Ltd.; Managing Executive Officer, Osaka Responsibility, MUFG Financial Group, Inc. Jun 2019 Representative Director, Senior Managing Executive Officer, Western Japan Regional Head, MUFG Bank, Ltd. Apr 2021 Representative Director, Deputy President and Executive Officer, Western Japan Regional Head, MUFG Bank, Ltd. Apr 2022 Vice Chairman, Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.; Western Japan Regional Head Apr 2025 Special Advisor, Mitsubishi UFJ Securities Holdings Co., Ltd. (current) Jun 2025 Outside Director, Nichicon Corporation (current) Sep 2025 Director, Ueda Memorial Foundation (current) Apr 2026 Part-time Vice President, Tohoku University (current) Jun 2026 Outside Director (Audit and Supervisory Committee Member), the Company (current)
1962-06-06
Large Shareholding Reports
Sumitomo Mitsui DS Asset Management Company, Limited
2026-07-06
5.15%→6.23%
Sumitomo Mitsui DS Asset Management Company, Limited
2026-02-05
5.15%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-06
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-07-06
Large Shareholding Report
EDINET
2026-06-22
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-02-13
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2026-02-05
Large Shareholding Report
EDINET
2025-11-11
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-07
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-24
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-13
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-13
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-08
Q1 Earnings Flash
FY ending Mar 2025
EDINETAmended
2024-07-10
Amended Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-06-26
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-14
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-28
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-14
Quarterly Securities Report
Period: Apr 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-06-27
Annual Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-08-13
Quarterly Securities Report
EDINET
2021-06-28
Annual Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →